This technology is a series of mitragynine analogs, altered for specific potency, efficacy and selectivity, for the treatment of pain and psychiatric disorders.
The dry leaf material of Mitragyna speciosa, or the Kratom plant, has a long history of medicinal use in humans. An increasing number of anecdotal reports have indicated its efficacy in treating diseases with very limited treatment options, including opioid dependence, treatment-resistant depression, anxiety, and pain. However, the clinical benefits of kratom are unclear due to the poor understanding of its biological and pharmacological effects.
This technology describes the synthesis of various analogs of mitragynine with defined pharmacological properties. The analogs possess substitutions that are key in tuning their potency, efficacy, and selectivity at opioid receptors. As such, the compounds described by this technology offer potential therapeutic leads for a number of psychiatric, pain, and substance abuse disorders.
Patent Pending (US20210179619)
IR CU16043, CU19033, CU18415
Licensing Contact: Jerry Kokoskha